By deploying and enhancing a liquid biopsy solution that requires only a simple blood draw for cancer treatment selection, Project ACTT will help eliminate the need for many patients to travel to hospital for surgical biopsies. emtelligent's NLP technology will help the consortium broaden the population of cancer patients who could benefit.
Tim O’Connell, CEO of emtelligent, says: "We're thrilled to be part of this exciting project. As a diagnostic radiologist, I am well aware of the limitations of our current methods for diagnosing cancer, and I worry about the impacts on cancer diagnosis and care that may be occurring during the current COVID-19 pandemic. Project ACTT holds the promise of bringing enhanced cancer diagnostics to Canada and we look forward to the opportunity to contribute to this valuable initiative."
Read more about Project ACTT here.